Based on the PERSONALIS INC. DL-001 stock forecasts from 0 analysts, the average analyst target price for PERSONALIS INC. DL-001 is not available over the next 12 months. PERSONALIS INC. DL-001’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of PERSONALIS INC. DL-001 is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, PERSONALIS INC. DL-001’s stock price was EUR 2.48. PERSONALIS INC. DL-001’s stock price has changed by -8.43% over the past week, -15.35% over the past month and 0% over the last year.
No recent analyst target price found for PERSONALIS INC. DL-001
No recent average analyst rating found for PERSONALIS INC. DL-001
Company Overview
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications, such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves pharmaceutical, biopharmaceutical, diagnostic testing, and biotechnology companies; healthcare providers; universities; non-profits; and government entities. The company was incorporated in 2011 and is headquartered in Fremont, California. Address: Read Less
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor a...Read More
N/A
N/A
395
N/A
EUR
Germany
Adjusted Closing Price
Loading...
Technical Indicators
Unadjusted Closing Price
Loading...
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Share Volume
Loading...
Relative Performance
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Stocks Similar To PERSONALIS INC. DL-001 (Sector: )
Stock Target Advisor's fundamental analysis for PERSONALIS INC. DL-001's stock is Neutral.
Unfortunately we do not have enough data on 04X:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 04X:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 04X:F's stock to indicate if its overvalued.
The last closing price of 04X:F's stock was EUR 2.48.
Unfortunately we do not currently have any market capitalization data for 04X:F's stock.
Unfortunately we do not have enough analyst data on 04X:F's stock to indicate whether its price will go up or not.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
There is nothing we particularly dislike
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 04X:F !
Please login to proceed
Sorry - extended search is only available for registered users.
